Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study

被引：0

作者：

Di Giacomo, A. M. ^{[1
]}

Simonetti, E. ^{[2
]}

Calabro, L. ^{[3
]}

Vegni, V. ^{[4
]}

Santangelo, F. ^{[5
]}

Depenni, R. ^{[6
]}

Colucci, M. ^{[2
]}

Valente, M. ^{[5
]}

Grifoni, R. ^{[7
]}

Lofiego, M. F. ^{[2
]}

Amato, G. ^{[5
]}

Keer, H. N. ^{[8
]}

Oganesian, A. ^{[8
]}

Chan, D. ^{[8
]}

Giannarelli, D. ^{[9
]}

Altomonte, M. ^{[5
]}

Ceccarelli, M. ^{[10
,11
]}

Anichini, A. ^{[12
]}

Covre, A. ^{[2
]}

Maio, M. ^{[1
]}

机构：

[1] Univ Siena, Univ Hosp Siena, NIBIT Fdn Onlus, Ctr Immunooncol,Oncol, Siena, Italy

[2] Univ Siena, Med Oncol, Siena, Italy

[3] Univ Ferrara, Med Oncol, Ferrara, Italy

[4] NIBIT Fdn Onlus, Radiol, Siena, Italy

[5] Univ Hosp Siena, Ctr Immunooncol, Med Oncol, Siena, Italy

[6] Univ Modena, Med Oncol, Modena, Italy

[7] Azienda USL Toscana Centro, Med Oncol, Florence, Italy

[8] Taiho Pharmaceut Inc, Clin Dev, Pleasanton, CA USA

[9] Fdn Policlin Gemelli, Biostat, Rome, Italy

[10] Univ Miami, Miller Sch Med, Computat Biol, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL USA

[12] Fdn IRCCS Ist Nazl Tumori, Expt Oncol, Human Tumors Immunobiol Unit, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2288

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA47

引用

页码：1237 / 1237

页数：1

共 50 条

[41] A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).
Long, Georgina V.
Atkinson, Victoria
Menzies, Alexander M.
Guminski, Alexander David
Sandhu, Shahneen Kaur
Brown, Michael Paul
Liaw, Tracy
Gonzalez, Maria
Davison, Jill
Paton, Elizabeth J.
Scolyer, Richard A.
Emmett, Louise
McArthur, Grant A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status
Shalata, Walid
Maimon Rabinovich, Natalie
Agbarya, Abed
Yakobson, Alexander
Dudnik, Yulia
Abu Jama, Ashraf
Cohen, Ahron Yehonatan
Shalata, Sondos
Abu Hamed, Ahmad
Ilan Ber, Tahel
Machluf, Oshri
Shoham Levin, Gal
Meirovitz, Amichay
CANCERS, 2024, 16 (10)
[43] Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Stratigos, Alexander J.
Sekulic, Aleksandar
Peris, Ketty
Bechter, Oliver
Prey, Sorilla
Kaatz, Martin
Lewis, Karl D.
Basset-Seguin, Nicole
Chang, Anne Lynn S.
Dalle, Stephane
Orland, Almudena Fernandez
Licitra, Lisa
Robert, Caroline
Ulrich, Claas
Hauschild, Axel
Migden, Michael R.
Dummer, Reinhard
Li, Siyu
Yoo, Suk-Young
Mohan, Kosalai
Coates, Ebony
Jankovic, Vladimir
Fiaschi, Nathalie
Okoye, Emmanuel
Bassukas, Ioannis D.
Loquai, Carmen
De Giorgi, Vincenzo
Eroglu, Zeynep
Gutzmer, Ralf
Ulrich, Jens
Puig, Susana
Seebach, Frank
Thurston, Gavin
Weinreich, David M.
Yancopoulos, George D.
Lowy, Israel
Bowler, Timothy
Fury, Matthew G.
LANCET ONCOLOGY, 2021, 22 (06): : 848 - 857
[44] Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
Tawbi, Hussein Abdul-Hassan
Forsyth, Peter A. J.
Algazi, Alain Patrick
Hamid, Omid
Hodi, F. Stephen
Moschos, Stergios J.
Khushalani, Nikhil I.
Gonzalez, Rene
Lao, Christopher D.
Postow, Michael Andrew
Atkins, Michael B.
Ernstoff, Marc S.
Puzanov, Igor
Kudchadkar, Ragini Reiney
Thomas, Reena Parada
Tarhini, Ahmad A.
Jiang, Joel
Avila, Alexandre
Demelo, Sheena
Margolin, Kim Allyson
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[45] Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.
Barroso-Sousa, Romualdo
Trippa, Lorenzo
Lange, Paulina
Andrews, Chelsea
McArthur, Heather L.
Haley, Barbara B.
Rugo, Hope S.
Emens, Leisha A.
Winer, Eric P.
Mittendorf, Elizabeth A.
Tolaney, Sara M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[46] Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
Fujimura, Taku
Kambayashi, Yumi
Ohuchi, Kentaro
Amagai, Ryo
Sato, Yota
Tanita, Kayo
Hashimoto, Akira
Aiba, Setsuya
CASE REPORTS IN ONCOLOGY, 2020, 13 (01): : 271 - 275
[47] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
Long, G. V.
Larkin, J.
Ascierto, P. A.
Hodi, F. S.
Rutkowski, P.
Sileni, V.
Hassel, J.
Lebbe, C.
Pavlick, A. C.
Wagstaff, J.
Schadendorf, D.
Dummer, R.
Hogg, D.
Haanen, J. B. A. G.
Corrie, P.
Hoeller, C.
Horak, C.
Wolchok, J.
Robert, C.
ANNALS OF ONCOLOGY, 2016, 27
[48] PD-L1 EXPRESSION AS A BIOMARKER FOR NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) AND NIVO ALONE IN ADVANCED MELANOMA (MEL): A POOLED ANALYSIS
Long, Georgina
Larkin, James
Ascierto, Paolo
Hodi, Stephen
Rutkowski, Piotr
Chiarion-Selini, Vanna
Hassel, Jessica
Lebbe, Celeste
Pavlick, Anna
Wagstaff, John
Schadendorf, Dirk
Dummer, Reinhard
Hogg, David
Haanen, John
Corrie, Pippa
Hoeller, Christopher
Horak, Christine
Wolchok, Jedd
Robert, Caroline
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 126 - 126
[49] A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1-refractory merkel cell carcinoma.
Shalhout, Sophia Z.
Emerick, Kevin S.
Kaufman, Howard E.
Miller, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
Lorenzen, S.
Thuss-Patience, P. C.
Folprecht, G.
Knorrenschild, J. Riera
Heinemann, V.
Goekkurt, E.
Dechow, T. N.
Ettrich, T. J.
Luley, K. B.
Moulin, J. C.
Lindig, U.
Angermeier, S.
Waidmann, O.
Pink, D.
Bolling, C.
Junge, S.
Pauligk, C.
Gaiser, T.
Goetze, T. O.
Al-Batran, S. E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1099 - S1099

← 1 2 3 4 5 →